Thomas R. Ulich
Nessuna posizione attualmente
Profilo
Thomas R.
Ulich worked as an Executive Vice President-Research & Development at ConjuChem Biotechnologies, Inc. from 2006 to 2010, Senior Vice President-Research & Development at Alnylam Pharmaceuticals, Inc. in 2003-2004, and VP-Preclinical Development & Protein Therapeutics at Amgen Canada, Inc. from 1993 to 2001.
He was also a Professor at Wayne State University and the University of California, Berkeley.
Ulich's education includes an undergraduate degree from Dartmouth College and a doctorate from the David Geffen School of Medicine.
Precedenti posizioni note di Thomas R. Ulich
Società | Posizione | Fine |
---|---|---|
INVIVO THERAPEUTICS HOLDINGS CORP. | Direttore Tecnico/Scientifico/R&S | 30/08/2017 |
ConjuChem Biotechnologies, Inc. /Old/
ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | Direttore Tecnico/Scientifico/R&S | 01/01/2010 |
ALNYLAM PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2004 |
Amgen Canada, Inc.
Amgen Canada, Inc. BiotechnologyHealth Technology Amgen Canada, Inc. operates as a biotechnology company. The company was founded in 1991 and is headquartered in Mississauga, Canada. | Direttore Tecnico/Scientifico/R&S | 01/01/2001 |
ConjuChem Biotechnologies, Inc.
ConjuChem Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals. Its peptide products are used to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. ConjuChem Biotechnologies is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. The company was founded on August 25, 2009 and is headquartered in Montréal, Canada. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Thomas R. Ulich
Dartmouth College | Undergraduate Degree |
David Geffen School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
INVIVO THERAPEUTICS HOLDINGS CORP. | Health Technology |
Aziende private | 3 |
---|---|
ConjuChem Biotechnologies, Inc. /Old/
ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | Health Technology |
ConjuChem Biotechnologies, Inc.
ConjuChem Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals. Its peptide products are used to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. ConjuChem Biotechnologies is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. The company was founded on August 25, 2009 and is headquartered in Montréal, Canada. | Health Technology |
Amgen Canada, Inc.
Amgen Canada, Inc. BiotechnologyHealth Technology Amgen Canada, Inc. operates as a biotechnology company. The company was founded in 1991 and is headquartered in Mississauga, Canada. | Health Technology |
- Borsa valori
- Insiders
- Thomas R. Ulich